View Future GrowthStarpharma Holdings 過去の業績過去 基準チェック /06Starpharma Holdingsは21.1%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.4%毎年増加している。売上は成長しており、年平均22.4%の割合である。主要情報21.06%収益成長率22.36%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率22.38%株主資本利益率-15.04%ネット・マージン-22.16%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Sep 18Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025.お知らせ • Oct 03Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024.お知らせ • Nov 11+ 1 more updateStarpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024Starpharma Holdings Limited announced the appointment of Ms. Cheryl Maley as Chief Executive Officer (CEO) of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.お知らせ • Oct 02Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time.お知らせ • Sep 19Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold VirusesThis winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated.お知らせ • Aug 28Starpharma Holdings Limited Announces Change of Company SecretaryStarpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6.New Risk • Jun 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$4.7m revenue, or US$3.2m). Market cap is less than US$100m (US$99.1m market cap).お知らせ • Jun 09Starpharma Announces Resignation of Jackie Fairley as Chief Executive OfficerStarpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.お知らせ • Feb 02Starpharma Holdings Limited Announces Board ChangesStarpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process.お知らせ • Jan 31Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years.収支内訳Starpharma Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:SPHR.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 2515-38030 Sep 2510-77030 Jun 256-106031 Mar 255-117031 Dec 244-137030 Sep 247-107030 Jun 2410-87031 Mar 2410-87031 Dec 2311-87030 Sep 238-127030 Jun 234-168031 Mar 235-168031 Dec 225-167030 Sep 225-167030 Jun 225-167031 Mar 225-177031 Dec 214-187030 Sep 214-197030 Jun 213-207031 Mar 213-197031 Dec 203-196030 Sep 205-176030 Jun 207-156031 Mar 207-146331 Dec 198-137530 Sep 195-147830 Jun 193-1461031 Mar 194-1361031 Dec 184-1161030 Sep 185-1151030 Jun 185-1051131 Mar 185-1251231 Dec 174-1351330 Sep 174-1441430 Jun 174-1541531 Dec 161-2041730 Sep 163-2041930 Jun 165-2142131 Mar 165-2252131 Dec 155-2042130 Sep 153-2041930 Jun 152-19416質の高い収益: SPHR.Fは現在利益が出ていません。利益率の向上: SPHR.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SPHR.Fは利益を出していないが、過去 5 年間で年間21.1%の割合で損失を削減してきた。成長の加速: SPHR.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: SPHR.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: SPHR.Fは現在利益が出ていないため、自己資本利益率 ( -15.04% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/27 00:19終値2026/06/23 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Starpharma Holdings Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Matthijs SmithCanaccord GenuityDerek JellinekCGS InternationalWaradana Malitha De SilvaCLSA6 その他のアナリストを表示
お知らせ • Sep 18Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025.
お知らせ • Oct 03Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024.
お知らせ • Nov 11+ 1 more updateStarpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024Starpharma Holdings Limited announced the appointment of Ms. Cheryl Maley as Chief Executive Officer (CEO) of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.
お知らせ • Oct 02Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time.
お知らせ • Sep 19Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold VirusesThis winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated.
お知らせ • Aug 28Starpharma Holdings Limited Announces Change of Company SecretaryStarpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6.
New Risk • Jun 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$4.7m revenue, or US$3.2m). Market cap is less than US$100m (US$99.1m market cap).
お知らせ • Jun 09Starpharma Announces Resignation of Jackie Fairley as Chief Executive OfficerStarpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.
お知らせ • Feb 02Starpharma Holdings Limited Announces Board ChangesStarpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process.
お知らせ • Jan 31Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years.